by Stacey Johnson | Oct 25, 2024
Michel Sadelain is the 2024 Gairdner International Award laureate, along with Dr. Zelig Eshhar, for his “seminal contributions to the conception, development and application of CD19-CAR T cell therapy for cancer.” It’s been a good year for Dr. Sadelain, who also won...
by Lyla El-Fayomi | Oct 10, 2024
“Regenerative medicine news under the microscope” is a monthly feature highlighting a selection of impactful research findings and headlines across the many subfields of regenerative medicine. Fall is finally here! September really delivered – lots of interesting...
by Laya Kiani | Sep 26, 2024
The regenerative medicine (RM) market is highly competitive, with major biopharmaceutical companies and innovative startups vying for dominance. As companies seek regulatory approval and work to establish their presence in this fast-evolving industry, the competitive...
by Lyla El-Fayomi | Sep 12, 2024
Welcome to a special edition of my blog that summarizes all the big news from the summer. I hope you’ve all been able to soak up (safely) as much sun as possible. Below, I cover the latest in aging, global trends in clinical trials for engineered biomaterials,...
by Peace Chukwu | Sep 5, 2024
From extracting insulin from the pancreas of cows to extreme diets and herbal remedies for glucose regulation, diabetes treatments over the century have evolved progressively, with each discovery extending the life span of patients a little longer than the last....
by Kevin Robb | Aug 22, 2024
Last month, the U.S. Food and Drug Administration (FDA) agreed to formally review a revised Biologics License Application (BLA) from Mesoblast for their mesenchymal stromal cell (MSC) product, remestemcel-L. The submission represents the third attempt by the company...
Comments